FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer<br><br>
FDA medical oncologists discuss the Sept 14, 2017, approval of MVASI, the first biosimilar approved in the US for the treatment of cancer.

FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer FDA medical oncologists discuss the Sept 14, 2017, approval of MVASI, the first biosimilar approved in the US for the treatment of cancer.

FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer

FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) is an FDA podcast series that provides information about new product approvals, emerging safety information for cancer treatments, and other current topics in cancer drug development.

Share FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer

Sign up to save your podcasts

FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer

FDA D.I.S.C.O.: First biosimilar approval for the treatment of cancer